Evidence map›Paper›PMID 40975172›Full record

ArticleThe Journal of biological chemistry2025

Rules of engagement: Determinants of chemokine receptor activation and selectivity by CCL27 and CCL28.

Mian Huang, Aura F Celniker, Rezvan Chitsazi, Douglas P Dyer, Ariane L Jansma, Irina Kufareva, Catherina L Salanga, Tracy M Handel

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Gut-Vagina Axis.Microorganisms · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mian HuangSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Aura F CelnikerSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Rezvan ChitsaziSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Douglas P DyerSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Ariane L JansmaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Irina KufarevaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA. Electronic address: ikufareva@ucsd.edu.
Catherina L SalangaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA. Electronic address: csalanga@health.ucsd.edu.
Tracy M HandelSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA. Electronic address: thandel@health.ucsd.edu.

Funding

STRUCTURE OF MACROPHAGE CHEMOTACTIC ACTIVATING PROTEINSR01AI037113 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M · 1995 to 2015
$5.2M
It's a tug of war: structure, consequences, and inhibition of CXCR4 and ACKR3 responses to lymphocyte chemoattractant CXCL12R01AI161880 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M, KUFAREVA, IRINA · 2021 to 2025
$3.4M
The structural plasticity of chemokine and gp120 recognition by CCR5R01AI118985 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M, KUFAREVA, IRINA · 2015 to 2019
$2.7M
Signaling circuits that drive cell movement and ligand scavenging by chemokine receptor CCR2R01GM136202 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M, KUFAREVA, IRINA · 2020 to 2023
$1.9M
Spatiotemporally resolved architecture of G protein signaling downstream of CXCR4, the driver of lymphocyte migrationR21AI156662 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUFAREVA, IRINA · 2021 to 2022
$434k
Computationally informed discovery of scavenging-sparing inhibitors of CC chemokine receptor 2R21AI149369 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUFAREVA, IRINA · 2020 to 2021
$434k
Dissecting the interactions of gp120 with chemokine receptor CXCR4R21AI121918 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M · 2016 to 2017
$426k
NIAID NIH HHS R01 AI037113NIAID NIH HHS R01 AI118985NIAID NIH HHS R01 AI161880NIAID NIH HHS R21 AI121918NIAID NIH HHS R21 AI149369NIAID NIH HHS R21 AI156662NIGMS NIH HHS R01 GM136202Wellcome Trust
6 · The paper itself

Abstract

The distinct functional roles of chemokines CCL27 and CCL28 in epithelial immunity of skin and mucosal tissues, respectively, are coordinated by their shared receptor, CCR10, and the CCL28-specific receptor, CCR3. To identify determinants of receptor activation, internalization and binding specificity, we conducted structure-function studies focused on the N termini of these two chemokines. Deletion of two N-terminal residues of CCL27 resulted in a CCR10 antagonist, highlighting the critical roles of these residues in driving receptor pharmacology. Extension with a Phe produced a CCR10 superagonist by occupying a unique subpocket in the receptor. Swapping the CCL28 N terminus onto the CCL27 globular domain (NT28-CCL27) also resulted in a superagonist of CCR10, but the opposite swap (NT27-CCL28) showed equivalent or reduced activity compared to WT CCL28, indicating that the CCL28 N terminus is a stronger driver of CCR10 signaling. The effects of these mutations were rationalized by AlphaFold models of the CCR10 complexes. Modeling also revealed that the reduced size of the binding pocket, and more basic nature of the N terminus and extracellular loops of CCR3 compared to CCR10, contribute to its specificity for CCL28 while CCR10 accommodates both ligands. The basic nature of CCL28 also contributes to its high affinity for glycosaminoglycans and is likely important for its retention in mucosal tissues. These data illustrate how the modular nature of these chemokines enables their overlapping but nonredundant functions, and how this modularity can be exploited to produce engineered chemokines for probing or targeting CCR10 in disease.

Indexed as

Chemokine CCL27Chemokines, CCReceptors, CCR10Receptors, CCR3AnimalsHEK293 CellsHumansCCL27 protein, humanCCL28 protein, humanCCR10 protein, humanCCR3 protein, humanChemokine CCL27Chemokines, CCReceptors, CCR10Receptors, CCR3AI-based interaction scoringAI-powered molecular modelingCC chemokine receptor type 10 (CCR10)CC chemokine receptor type 3 (CCR3)CCL27CCL28cell migrationglycosaminoglycanG protein-coupled receptor (GPCR)structure-functionsuperagonist

Identifiers

PMID40975172
PMCPMC12556802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.